The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
I believe the trial is also about "early efficacy".
Can't see dosage increases being allowed if there weren't signs of early efficacy and believe this would be a factor for the FDA in granting orphan drug status.
Just a thought.
Onwards Avacta.
Best not under estimate how well this trial is going unless you have a "hidden" agenda.
The reduction in cytotoxicity is being well under estimated ( in my humble opinion).
Why else would cohort 4 be going ahead at 200mg?
Onwards Avacta.
... sp fluctuations and various negative posters, we have a fantastic opportunity here with regards to cancer treatment. For patients this is brilliant.
For those with shares, the sky is the limit as we have an approach that is way safer than what has been used before. The issue with doxorubicin is the effect on other organs, particularly the heart.
The reduced toxicity of AVA6000 is key.
Onwards Avacta.
... and still worth reading again:
https://aacrjournals.org/cancerres/article/82/12_Supplement/1815/700880
Onwards Avacta.
... reading again ...
https://aacrjournals.org/cancerres/article/82/12_Supplement/1815/700880
Particularly the toxicity comments.
Onwards Avacta.
... not the daily sp fluctuations.
We all know the last few RNSs have been very positive despite the fluctuations.
AVA6000 is clearly better than doxorubicin on its own or we wouldn't have the dose escalations.
Onwards Avacta.
PS - you get banned if you post level 2 data or I would.
... over the pond ...
https://www.nasdaq.com/articles/avactas-ava6000-gets-fda-orphan-drug-designation-to-treat-soft-tissue-sarcoma-stock-up
Onwards Avacta.
... the wrong RNS?
I thought that the one I read said:
a) Moving to cohort 4
b) As approved by the Safety Data Committee
c) On plan, or even ahead of plan
Instead, the discussion board is on about alleged shorters and we appear to have attracted many that want a lower entry point.
Well, I think I will stick with my belief that:
a) This trial is working.
b) You don't announce the next AVA drug if it isn't working.
c) You don't bother having a pipeline of AVA drugs.
I must live in an alternative world. Happy in that alternative world.
Onwards Avacta.
Hiya, gmcc,
I also used to wonder why all sites aren't shown as recruiting but don't now.
My rationale is that we know that the intended number of patients for the next phase is @80 and that is across eight sites including the two in the US.
Other factors are:
a) Some sites specialise in certain cancers.
b) We don't need eight sites at this stage.
I have also seen The Beatson (Glasgow) advertising for both head and and breast cancer volunteers.
As DTW rightly said, we just need to watch the science and not the daily sp fluctuations.
Onwards Avacta.
Perhaps Martin Walton is talking to Mike Owen on occasion.
https://www.reneuron.com/about-us/board-of-directors/
Onwards Avacta.
https://www.proactiveinvestors.co.uk/companies/news/213871/avacta-says-partner-moderna-takes-collaboration-to-next-level-213871.html
Worth looking at why Moderna are sueing.
Have a great weekend. Just off to help Ripley out.
Onwards Avacta.